RE:Leadership changes at RochePharmaceuticals are OUT! Meanwhile Biologics and Biopharmaceuticals are IN !
And in Roche's case their failed bet on Alzheimer's disease at the expense of oncology has resulted in Anderson's sudden departure. As reported in the attached link ..." Bill Anderson, the former boss of Roche's Genentech unit, would quit at the end of the year "to pursue opportunities outside of Roche", with a successor due to be named by March 2023, Roche said in a statement.
Anderson's departure from heading Roche's largest business means more fundamental change to manage for CEO-designate Thomas Schinecker, Roche's head of diagnostics, who is due to be promoted to group CEO in March.
He will replace CEO Severin Schwan, who has led a successful years-long campaign to diversify away from Roche's traditional focus on cancer.
But the onus will be on Schinecker to reinvigorate the development pipeline after family-controlled Roche this year ran into a string of development setbacks: A keenly-followed Alzheimer's drug trial failed last month and a new lung cancer immunotherapy candidate flopped in May.
Anderson joined California-based Genentech in 2006 as senior vice president of the Immunology and Ophthalmology Business Unit, before leading the Bio oncology Business Unit.
He had been CEO of Roche's pharmaceuticals business since 2019."
https://www.saltwire.com/cape-breton/business/roche-names-new-ceo-with-schwan-set-to-become-chairman-100804845/
[ Roche's C-suite 'epochal tectonic shift' should place ONCY in a better negotiation position , since Roche is in greater need to bring their oncology pipeline to the forefront, with growing dependence on the success of their PD-1 checkpoint inhibitor Tecentriq. ]